A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects
Dollerup OL, Christensen B, Svart M, et al. American Journal of Clinical Nutrition 2018;108:343-353.
What it found
Precursor study (NR). No serious adverse events and normal safety blood tests, but no improvement in insulin sensitivity, glucose handling, energy expenditure, fat burning or body composition.
Limitations
Men aged 40 to 70 with obesity only; moderate size.
Research and education only. Not medical advice. Many peptides on this site are not approved by the FDA for human use. Doses shown are the ones used in published studies and are not a recommendation. Talk to a licensed clinician before using any of them. Read the full disclaimer.